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A workshop was held to discuss potential advancements to improve the precision of risk estimates
for developmental toxicity. This paper presents an overview of the discussions at the workshop,
focusing on the risk assessment process and science policy considerations important in the use of
quantitative models. Some of the pertinent biological considerations are reviewed, particularly those
related to the repair capacity of the developing organism and how this affects the concept of a
threshold for developmental toxicity effects, as well as the maternal and litter influences on
developmental toxicity outcomes. Finally, the current status of use of quantitative approaches is
described, possible short-term approaches are discussed, and future research needs in this area are
outlined.
Introduction
Over the past 2 years, an Environmental Protection
Agency (EPA) working group on Approaches to
Quantitative Reproductive Risk Assessment has been
evaluating various approaches to improve the pre-
cision of risk estimation in reproductive and develop-
mental toxicology. The workshop summarized here
was an outgrowth of those considerations and focused
on the area of developmental toxicology because the
strongest data bases that are most amenable to risk
estimation are available in this area. The workshop
was held May 7-8, 1987, at the Stouffer's Concourse
Hotel, Crystal City, VA. Invited speakers and partici-
pants included reproductive and developmental toxi-
cologists, epidemiologists, and statisticians both from
EPA and from outside the Agency. This workshop was
the first of a series to discuss the development and use of
more quantitative models for risk assessment in re-
productive and developmental toxicology, to consider
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approaches that may be useful in the near future, and
to stimulate research in the area.
Several ofthe speakers at the workshop reviewed the
important risk assessment and science policy issues, as
well as underlying biological assumptions and un-
certainties. This overview represents a synthesis of
these presentations. Four papers that accompany this
overview address specific approaches that have been
used in the mathematical evaluation of data in the
area ofdevelopmental toxicology (1-4).
Risk Assessment and Risk
Assessment Guidelines
In 1986, the EPA published guidelines for risk as-
sessment in five areas (5): carcinogenesis, develop-
mental toxicity, mutagenesis, chemical mixtures, and
exposure. Additional guidelines on male and female
reproductive toxicity and on systemic toxicity are in
preparation. These guidelines present the scientific
principles and inferences used by the Agency in con-KIMMEL ETAL.
ducting risk assessments. They also are intended to
promote quality and consistency in assessments across
programs within and outside the EPA. The guidelines
were developed based on the principles set forth by the
National Academy of Sciences in their effort to describe
the risk assessment process in the federal government
(6). In that document, four components were identi-
fied: hazard identification, dose-response assessment,
exposure assessment, and risk characterization. The
hazard identification and dose-response assessment
are closely tied and represent the first steps in de-
scribing the animal data. For the vast majority of
chemicals, the data base available is totally derived
from animal studies. In the exposure assessment, the
level of human exposure from all potential sources is
estimated. The final stage of the process, risk charac-
terization, summarizes what is and is not known
about particular chemicals and their impact on ani-
mals and humans; it evaluates the hazard in light of
the estimated level of human exposure and describes
the assumptions used and uncertainties in the delin-
eation of risk. The risk characterization is used by risk
managers to assist in the formulation of regulatory
decisions.
The Guidelines for the Health Assessment of Suspect
Developmental Toxicants define developmental toxi-
city broadly to include adverse effects on the developing
organism that may be manifested as deaths, structural
abnormalities, altered growth and/or functional defi-
cits (7). Thus, developmental toxicity includes a vari-
ety of types of outcomes and does not focus only on
birth defects. Exposure may occur prior to conception
(to either parent), during prenatal development, or
postnatally to the time of sexual maturation. In addi-
tion, developmental effects may be detected at any point
during the lifespan of the organism, although effects
manifested months to years postnatally are more diffi-
cult to link with a specific exposure.
In the extrapolation of risks for developmental toxi-
city, the approaches currently used are outlined in the
developmental toxicity risk assessment guidelines (7).
One approach is the application of an uncertainty fac-
tor to the NOEL (no-observed-effect level) for the most
sensitive animal species tested. The uncertainty factor
is usually composed of a 10-fold factor to account for
interspecies differences and a 10-fold factor for intra-
species variability. If a NOEL is not available, then an
additional 10-fold factor may be applied to the LOEL
(lowest-observed-effect level). The other approach is the
calculation of a margin of safety (MOS), which is the
NOEL divided by the estimated level of human ex-
posure from all potential sources. The MOS can then be
evaluated for adequacy to protect human health. There
are several drawbacks to either ofthese approaches, the
primary one being that they use only one point on the
dose-response curve (NOEL or LOEL) and ignore the
rest of the data. Also, since the variability around the
NOEL/LOEL is usually not taken into account, these
approaches may reward poor studies, i.e., studies that
result in a higher NOEL because of their limited
ability to detect small changes over background.
The initial efforts in quantitative extrapolation from
high doses conventionally used in animal studies to
low environmentally relevant doses and across species
were made in the area of carcinogenicity. There are a
number of critical differences in the inferences made
for carcinogenicity compared with other types of
toxicity, the primary difference being the assumption
that there is essentially no threshold for carcinogen-
icity. For all types of toxicity except carcinogenesis and
mutagenesis, the assumption is generally made that
there is a threshold, i.e., a level below which one would
not expect to observe an effect. These differences in the
underlying assumptions made for carcinogenicity
and for other forms of toxicity thus make it inappro-
priate to apply the same kinds of techniques for extrap-
olation in all areas. Therefore, better definition of ap-
propriate means for extrapolation of noncancer effects
is needed, particularly in the areas of reproductive and
developmental toxicity.
Risk assessment for developmental toxic effects also
differs from that of carcinogenesis in that the effect
under study occurs in a different unit (embryo/fetus
or offspring) than the unit that is exposed (parent).
This leads to very different data structures for develop-
mental toxicity and carcinogenesis laboratory studies.
Observations in the former are on individual mem-
bers ofeach litter, and, because ofintralitter relatedness,
are not independent. This presents serious complica-
tions in modeling the dose-response relationship and
eliminates the statistical methods used in carcinogenic
risk assessment.
Science Policy Issues
During the last decade, the EPA and other federal
health and safety regulatory agencies have focused
much of their attention on the control of chemical car-
cinogens. The frequency of cancer, the fact that it is
difficult to detect early and treat, and, as a consequence,
is often fatal, have produced a high level of public
concern. This is reflected in a number of congressional
mandates that EPA and other agencies implement to
deal with the risks of cancer. The regulation of
carcinogens has been aided to a large extent by the
elucidation of mechanisms of carcinogenesis and the
incorporation of this information into quantitative
models that can be applied consistently to estimate risk
for carcinogenesis.
However, serious health effects other than cancer also
place social and economic burdens on society. For
example, it is estimated that 6% of live births per year
in the U.S. have congenital defects that are identifiable
in the first year of life. This number approximately
doubles with advancing age, and close to one-half of all
hospital beds in children's wards are occupied by
individuals with congenital defects (8). The etiology of
only about one-third of the cases is known, and envi-
ronmental agents and drugs account for only 4 to 5% of
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all developmental defects (9). Since adverse develop-
mental effects generally are manifest early in life, the
result is often many years of suffering at a great
health-care costto society.
The Agency has been using traditional margin-of-
safety (MOS) methods for developmental toxicity effects
for some time; however, there are several advantages
for moving beyond the MOS and uncertainty factor
methods. For example, a quantitative risk assessment
for developmental toxicity effects is an important step
toward refining the dose-response relationship and
interpreting scientific data for setting standards for
human exposure. It should allow a more precise esti-
mation of the risk at doses where human exposure can
be expected to occur. It makes more complete use ofthe
dose-response data by considering the slope of the esti-
mated dose-response curve, the spacing of the experi-
mental doses, and the number of animals tested,
whereas the MOS approach relies primarily on the use
of the NOEL. Ultimately, quantitative risk assessment
provides a basis for comparing hazards from different
substances in a controlled and predictable manner and
thus can be used to set priorities for the allocation of
resources ofboth theAgency and society.
As the scientific basis ofquantitative risk assessments
for adverse developmental effects continues to develop,
certain science policy issues and critical questions
must be addressed. Decisions will have to be made
about which model is the most appropriate for the bio-
logical processes of concern. What criteria have to be
met for scientists to recommend a quantitative model
for risk assessments on developmental toxicants? Are
different models required for different outcomes, e.g.,
birth defects, low birth weight, reduced prenatal and
postnatal survival, reduced functional capacity? The
issue of threshold must also be addressed. Because a
threshold is generally assumed for developmental tox-
icity effects, the incorporation of such an assumption
will affect the risk estimates obtained from the model.
Should threshold considerations be incorporated into
the model or should no threshold be assumed as is
done in the cancer model? Of course, any model(s) that
are chosen by the Agency should not be static but have
the potential for incorporating new information.
The development of quantitative risk assessment
methods for developmental toxicants is an encourag-
ing trend, correcting what many believe has been an
unbalanced focus on cancer. The use of quantitative
risk assessments for prioritizing the risk of exposure to
developmental toxicants will enable federal agencies to
better assess social and economic priorities and provide
the most efficient use of the resources available for our
health and environmental quality.
Biological Considerations for
Developing Quantitative Models
Several issues considered at the workshop related to
biological considerations important in the develop-
ment of quantitative risk assessment models for devel-
opmental toxicity. These included the repair capacity of
the developing organism, how this affects the concept of
a threshold for developmental toxicity effects, and the
role of the maternal and litter influence on develop-
mental toxicity outcomes.
Mechanisms of Developmental Toxicity
and Repair
A variety of mechanisms have been suggested as the
causation of birth defects. Genetic (mutation, chromo-
some nondisjunction, altered gene function), as well as
nongenetic events (insufficient supply of energy
sources and substrates, enzyme inhibition, altered cell-
to-cell contact, and osmolar imbalance), have been de-
scribed for compounds possessing teratogenic activity
(9). Despite the diversity of initial cellular reactions, a
common final pathway involving insufficient cells or
cell products to carry out morphogenesis is believed to
exist, although a complete understanding of the
sequence ofevents leading to teratogenesis has not been
accomplished with any agent. Depressions of DNA
synthesis as well as DNA damage do not appear to be as
important as increased cell death in the initiation of
teratogenic damage. For example, the embryo can
tolerate substantial depressions in DNA synthesis,
which, unless accompanied by excessive necrosis, do
not lead to malformations (10,11).
The induction of teratogenic damage at the cellular
level is clearly a multistage process wherein a sequence
of events must occur before the final malformation is
expressed. At the organ/whole embryo level, Fraser
(12) described and empirically demonstrated the
multifactorial/threshold concept based on cortisone
induction of cleft palate in mice. According to this con-
cept, both genetic and extrinsic factors may influence
the final outcome and thus affect the threshold dose. In
this scenario, a critical mass of cells must be affected
before a threshold is crossed and dysmorphogeneic
processes are set in motion. This model for the in-
duction of developmental toxicity is in contrast with
the concept developed for carcinogenesis where a single
hit, a single molecule, or a single unit of exposure is
believed to be sufficient to initiate the transformation
process.
For some time, it has been recognized that com-
pensatory growth, or increased mitotic activity, occurs
in embryonic tissue after teratogenic insult. Snow has
used the term "restorative growth" to describe the
process whereby mammalian embryos replace cells lost
through tissue damage or deficit (13,14). Enhanced
cell proliferation may be observed in every tissue of the
embryo with increased necrosis, although malforma-
tions only occur at specific sites of damage. Differential
cell death, most likely due to differences in cell cycle
characteristics, is the necessary prerequisite and initial
trigger to restorative growth. As a result of differential
cell death, imbalance is created among cell types in a
tissue and/or organs within an embryo. The result is
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an uncoordinated growth process that is likely to cause
mistiming of inductive interactions between tissues
that are initially perturbed by differential cell death.
There have been a number of attempts to measure
DNA damage and repair in embryonic tissues follow-
ing treatment with cytotoxic teratogens (15,16). Even
though DNA damage has been identified by a variety
of techniques, measurement of DNA repair has been
hampered by the cell death caused by these agents. Dis-
appearance of DNA damage cannot be clearly attributed
to cellular repair processes or to removal ofaffected cells
from the population through necrosis. Even in cases
where DNA damage has been shown to persist after the
necrotic episode, it has not been possible to correlate it
with dysmorphogenesis. Consequently, little is un-
derstood about repair processes at the cellular level be-
yond restorative growth.
Consideration of the Threshold Concept
for Developmental Toxicity
The concepts developed concerning induction and
repair of prenatal toxicity have led to formulation by
Wilson of the following major principle of develop-
mental toxicology (9): "Manifestations of deviant
development increase in frequency and degree as
dosage increases from the no-effect to the totally lethal
level." Developmental toxicologists have generally
assumed that all agents causing prenatal toxicity do
have a threshold below which no effect of any kind can
be demonstrated. This assumption is based on the bulk
of developmental toxicity studies conducted since 1966
in which embryolethality and malformations were
measured. Dose-response curves in developmental
toxicity studies are typically steep, and embryotoxic
responses depend upon the reaction of integrated
groups ofcells, tissues, and organs (17).
While the existence of thresholds for the dichoto-
mous responses of malformation and embryolethality
is generally accepted, the continuous variable of
growth retardation has not been subjected to the same
scrutiny. Conceptually, a threshold should exist for
growth retardation insofar as a number of events
must occur and accumulate before growth retardation
is manifest.
The safety factor approach used by regulatory agen-
cies assumes thatthe specified acceptable exposure level
for a developmental toxicant is below the threshold dose
of most if not all exposed members of the population.
Kaplan et al. (18) have studied the validity of this
assumption under a simple model that describes the
variability of individual threshold doses in the hu-
man population. Their results show that the fraction of
the population whose threshold doses are below an
acceptable exposure level may be significant and repre-
sent an upper bound on the added population risk
resulting from exposure to the toxicant. They also
suggested that there are instances when the traditional
safety factor of 100 may be inadequate. For example, if
the slope of the experimental dose-response curve is
shallow or if there is evidence that the animal thresh-
old is well below the lowest experimental dose con-
sidered, then a safety factor larger than the traditional
value may be necessary. In other cases, the conclusions
are more equivocal, and so the safety factor of 100 may
or may not be adequate. Estimation of the risk asso-
ciated with a given acceptable exposure level using an
appropriate model would aid in the evaluation of the
additional risk that might be incurred if a threshold
assumption was not appropriate.
Maternal and Litter Influence on
Developmental Outcomes
A number of maternal factors are known to have
significant bearing upon the outcome of standard
developmental toxicity bioassays (as well as on human
births). For example, the role of the genetic makeup of
the pregnant female and fetus has long been known to
be of crucial importance in developmental responses to
exogenous agents. In both laboratory and epidemi-
ological studies, researchers have demonstrated that
there are maternal heritable factors that may sig-
nificantly alter the probability of defects in the off-
spring. Maternal disease concurrent with pregnancy
also may significantly affect in utero development. For
example, rubella infection, cytomegalovirus, and
toxoplasmosa in humans, as well as mycoplasma and
cytomegalovirus in mice, have been shown to cause
developmental toxicity (19). In most cases, it is difficult
to differentiate between direct fetal effects and those
induced secondarily as a result of maternal disease. A
wide spectrum of dietary insufficiencies ranging
from protein-calorie malnutrition to significantly
reduced quantities of vitamins, trace elements and/or
enzyme cofactors (20,21) also are known to adversely
affect normal embroyo/fetal development. In addition,
there have been numerous studies that examined the
effects of maternal stress on embryo/fetal outcome and
suggested the association of various forms of stress
with adverse effects in the developing system.
Of the factors discussed, genetics and disease are of
relatively little practical significance in laboratory
studies since these factors are controlled to a consider-
able extent by the use of genetically well-defined and
healthy laboratory animals. Given both the overt ma-
ternal toxicity called for by the vast majority of devel-
opmental toxicology protocols used for regulatory
purposes and the current lack of knowledge of basic
mechanisms involved in developmental toxicity, the
question of the effects of maternal toxicity and atten-
dant stress is a critical one about which little is known.
Data derived from populations of animals where
severe maternal toxicity has occurred must be inter-
preted carefully untiltit is possible to distinguish those
embryo/fetal effects associated with such toxicity.
Maternal toxicity and/or stress are extremely difficult
to define, and while all may agree that a decrease in
maternal weight gain or an increase in death may be
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clear manifestations of toxicity, there may be con-
siderable debate concerning other agent-induced
maternal effects such as decreased plasma cholin-
esterase or hepatic hypertrophy or hypo/hypertension.
Another important point is that many human
developmental toxicants act at or very near the mater-
nally toxic dose level (e.g., alcohol, methylmercury,
chemotherapeutics) so that the presence of maternal
toxicity should not invalidate the data generated at
that dose level. Research efforts should be directed
toward the identification of developmental effects that
are associated with either well-defined types of mater-
nal toxicity or general stress induced by such toxicity.
The attempt to extrapolate risk from laboratory ani-
mal species to man must deal with the problem created
by attempting such comparisons between species in
which large litters are commonplace and a species
where multiple births are a rarity. There has, among
teratologists, been an ongoing debate concerning the
proper experimental unit upon which to base statistical
analyses. Haseman and Hogan (22) and Haseman and
Soares (23) investigated this issue using data from
studies on dieldrin or dipterex. They concluded that
individual malformed fetuses or fetal deaths did not
result independently as experimental units and thus
should not be regarded as the basic sampling unit. A
method for data analysis of populations with greater
variation than would be predicted by a simple bi-
nomial model (such as animal litters) has been
recently published by Pack (24). This method takes
both inter- and intralitter incidences of experimental
effects into account. The accompanying paper by
Chinchilli and Clark (3) also discusses this issue.
Summary of Workshop
Discussions: Current Status and
Future Directions
Short-Term Approaches
A number of issues were discussed at the workshop
and numerous questions were raised concerning
future research needs. Approaches were proposed by
Gaylor (2) and by Faustman et al. using the Rai and
Van Ryzin model (1); either of these, or possibly some
combination of the two, should be considered further.
However, there are still problems to be addressed. For
example, the models as presented use data from studies
in which all pups within each litter have been
examined for all types ofeffects. These data are available
if one uses the fresh visceral dissection technique (25).
However, in many laboratories using the Wilson
technique (26), pups within litters are divided into
groups for examination of visceral or skeletal defects.
How does dividing litters so that not all types of data
are available on all pups affect the risk estimates that are
derived? Also, more work is needed on litter size
considerations, how intralitter correlations may affect
the models and the risk estimates and on the use of
litter data from animal studies for extrapolation to
humans, for whom single offspring are usually
derived from each pregnancy. The accompanying
papers by Chinchilli and Clark (3) and Butler and
Kalasinski (4) address certain aspects ofthis issue.
Philosophical Considerations
There are also important philosophical considera-
tions related to the way in which risk estimates are
presented to the risk manager and to the public. For
example, in the approach currently used, an exposure
level is derived (Reference Dose, Acceptable Daily
Intake) below which no increased risk above
background levels would be expected, based on the
current assumption of a threshold. However, in using
a more quantitative approach, a risk estimate is
derived (e.g., no greater than 1 in 104) that implies
some level of residual risk even though the dose level
may be the same as that obtained using uncertainty
factors and assuming a threshold. The presentation of
such risk estimates will require careful thought and
some level of education. Also, scientists and health care
specialists must consider what would be an acceptable
level of risk, based on background levels and what is
known about the biological processes underlying these
phenomena. Currently used procedures of 100- to 1000-
fold safety factors reduce the estimated risk levels to a
range of no more than 1 in 1000 to 1 in 10,000 cases
(27). Isthislevelofriskacceptable?
Policy Considerations
Obviously, there are also policy considerations to be
made concerning the use of models. For example,
when is enough information available to begin using
an approach or a model? How much validation is
necessary to begin using an approach? Is a threshold
assumption too conservative for these types ofeffects? In
other words, how often can we be certain of setting
acceptable levels low enough to protect the majority of
the population?
Future Research Needs
A number of points were raised in the workshop that
require further research. Obviously, further testing of
the models currently being developed is called for,
using more data sets including those that are less
robust than the ones previously used, and determin-
ing whether more dose levels would add significantly
to the precision ofthe risk estimates from these models.
Secondly, an issue of great importance is the rela-
tionship among various end points (e.g., the rela-
tionship of maternal and developmental toxicity, the
relationship among various end points of develop-
mental toxicity, etc.), and how these relationships affect
the type of dose-response models used and the estima-
tions of risk. As Selevan and Lemasters (28) point out,
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end points observed at birth are the result of a long and
complex process. The process yielding one type of ad-
verse effect may result from a number of factors. Avery
high exposure could result in early fetal loss, while a
lower one might result in a congenital malformation
observed at birth. Thus, the probability of a congenital
defect might fall with increasing exposure due to the
increasing probability of fetal loss, resulting in an
inverted U-shaped dose-response curve for the inci-
dence of congenital malformations. This requires that
assessment of the risk of malformations include ad-
justment for mortality. Thus, the patterns of these
interrelationships is important in the development of
appropriate dose-response models for developmental
toxicity end points.
Third, the development of more standard approaches
is needed for using pharmacokinetic data to determine
dosimetry and to better define dose-response relation-
ships. Although there has been much discussion about
how pharmacokinetics would be useful in this respect
(29), very little has been done to apply these techniques
in the regulatory setting.
Fourth, heterogeneity within the human popula-
tion in terms of sensitivity to toxic agents tradition-
ally has been accounted for using a 10-fold factor in the
risk assessment process. In the case of developmental
toxicity, where estimates of the incidence of spontane-
ous abortion range from 30 to 80%, is it appropriate to
assume that the variability within the human popu-
lation really falls within an order of magnitude?
Clinicians routinely make estimates about the risks for
various types of malformations in children. Would
the data on which these estimates are based be useful in
determining the range of sensitivity of the human
population?
Finally, the use of more biologically based models
was discussed. Of course, in order to develop such
models, a good deal of information is needed on the
underlying biological processes and mechanisms of
toxicity. Unfortunately, very little is known about
mechanisms of developmental toxicity, but more
information is being gathered about the underlying
developmental processes involved [e.g., the restorative
growth concept (14)1. How much of this type of infor-
mation could be brought to bear on the development of
biologically based models for developmental toxicity
effects?
In summary, this workshop brought together
reproductive and developmental toxicologists, epi-
demiologists, and statisticians to examine ways to
improve estimations of risk for human developmental
toxicity. Experience in the quantitation of carcino-
genesis risks was considered in these discussions. As
stated earlier, this workshop was seen as the first in a
series of such efforts to focus attention in this area and
to encourage research. It is hoped, this goal will be
fulfilled and future workshops and symposia on this
topic will see the development and application of
approaches for the regulatory setting.
The views in this paper are those of the authors and do not neces-
sarily reflect the views or policies of the U.S. Environmental Protection
Agency.
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